News & Events
Found a way to reverse the resistance of tuberculosis to antibiotics
- January 4, 2020
- Posted by: Wiley M. Wagner
- Category: Science
Tuberculosis is one of the most infectious diseases in the world, organized with the help of the corresponding bacteria of the Mycobacterium tuberculosis family – thus killing more than 1.5 million lives every year. Despite the fact that at this point in time, tuberculosis is almost completely treatable, nevertheless, it is not so easy to defeat its key parent bacterium, primarily because it has the ability to quickly overgrow with a protective biofilm, thus preventing its destructive effect from modern antibiotics. However, a team of specialists from the United States found a way around this protection.
And the method itself consists in preventing the very property of a given bacterium from forming a protective biofilm around itself. To begin with, the research team analyzed more than 91 chemical compounds whose chemical structure is closest to the indicated tuberculosis bacterium, and whose effectiveness has already been tested repeatedly in the fight against other dangerous bacteria. And they really found the most promising compound called C10, which just focuses on preventing the bacteria from fouling with a protective biological film, which he copes with at the proper level, which was tested during tests in the laboratory.
Bacteria pneumonia, medical concept, 3D illustration showing human lungs and close-up view of rod-shaped bacteria in lungs
Moreover, in their own laboratory tests, the specialists decided to add a certain part of the C10 substance to a certain number of antibiotics that fight against similar bacteria – such as isoniazid. After conducting the second stage of their clinical research, the specialists actually managed to significantly destroy most of the bacterial colonies.
Thus, they proved that such a combo of substance C10 and any more or less potent antibiotic is sufficient to effectively fight and destroy even the most protected colonies of tuberculosis bacteria, since the substances weaken their natural defense and allow the antibiotic to carry out its work. Thus, it remains only to wait for the moment when the development will be further improved for clinical trials.